---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-017392"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:52:33.339519+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Athira reports Q2 net loss $24.3M; ACT-AD Phase 2 Alzheimer's trial missed primary endpoint

## Summary
- Net loss $24.3M ($0.65/share) vs $14.0M ($0.38/share) in Q2 2021; cash $282.2M.
- ACT-AD Phase 2 trial of fosgonimeton did not meet primary endpoint (P300 latency).
- Monotherapy subgroup showed ADAS-Cog11 improvement of -3.3 points vs placebo (not significant).
- Statistically significant reduction in plasma NfL biomarker in monotherapy subgroup (p=0.018).
- LIFT-AD Phase 3 enrollment ongoing; over 300 patients enrolled as of report date.

## SEC filing metadata
- accession: 0000950170-22-017392
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000095017022017392/0000950170-22-017392-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000095017022017392/atha-20220815.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-017392
- JSON: https://secwatch.observer/filing/0000950170-22-017392.json
- Plain text: https://secwatch.observer/filing/0000950170-22-017392.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.